Author： Ragnar Norrby S.
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.22, Iss.3, 2000-03, pp. : 191-194
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Access to resources
Recommend
Risk-Benefit Assessment of Therapies for Mycobacterium avium Complex Infections
Drug Safety, Vol. 21, Iss. 2, 1999-08 ,pp. :
A Risk-Benefit Assessment of Abciximab in Angioplasty
By Kleiman N.S.
Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. :
A Risk-Benefit Assessment of Amifostine in Cytoprotection
By Mabro M.
Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. :
A Risk-Benefit Assessment of Antileukotrienes in Asthma
By Smith L.J.
Drug Safety, Vol. 19, Iss. 3, 1998-09 ,pp. :